A silica-induced pulmonary fibrosis model: Are we closer to 'real life'?

International Archives of Allergy and Immunology

Volumn 158, Issue 3, 2012, Pages 211-212

  Fireman, E ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; PRANLUKAST; SILICON DIOXIDE;

ACUTE LUNG INJURY; DISEASE COURSE; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG PARENCHYMA; MORTALITY; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; CHROMONES; FEMALE; LEUKOTRIENE ANTAGONISTS; PULMONARY FIBROSIS; SILICON DIOXIDE;

EID: 84857479013     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000335237     Document Type: Editorial

References (12)

1. Kuhn C: Pathology; in Phan S, Thrall R (eds): Pulmonary Fibrosis. New York, Dekker, 1995, pp 59-83.
2. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151. (Pubitemid 32096342)
3. Katzenstein ALA, Fiorelli RF: Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-147. (Pubitemid 24046413)
4. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C: Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163: 1648-1653. (Pubitemid 32578771)
5. Shimbori C, Shiota N, Okunishi H: Pranlukast, a cysteinyl leukotriene type 1 1 receptor antagonist, attenuates the progression, but not the onset, of silica-induced pulmonary fibrosis in mice. Int Arch Allergy Immunol 2012;158:241-251.
6. Davis GS, Leslie KO, Hemenway DR: Silicosis in mice: effects of dose, time, and genetic strain. J Environ Pathol Toxicol Oncol 1998; 17: 81-97. (Pubitemid 28168809)
7. Oberdorster G: Significance of particle parameters in the evaluation of exposure-doseresponse relationships of inhaled particles. Inhal Toxicol 1996; 8: 73-89.
8. Barbarin v, Nihoul A, Misson P, Arras M, Delos M, Leclercq I, Lison D, Huaux F: The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis. Respir Res 2005; 6: 112.
9. Barbarin v, Xing Z, Delos M, Lison D, Huaux F: Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol 2005; 288:L841-L848.
10. Misson P, Brombacher F, Delos M, Lison D, Huaux F: Type 2 immune response associated with silicosis is not instrumental in the development of the disease. Am J Physiol Lung Cell Mol Physiol 2007; 292:L107-L113. (Pubitemid 46103436)
11. Chua F, Gauldie J, Laurent GJ: Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33: 9-13. (Pubitemid 40961008)
12. Hunninghake GW, Schwarz MI: Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc 2007; 4: 449-452. (Pubitemid 47435370)